Stock Forecast

  Bolt Biotherapeutics, Inc. ( BOLT) Stock. Should you Buy or Sell?    $ 1.77

-0.03 (-1.72 %)



Bolt Biotherapeutics, Inc. Analysis

Updated on 10-09-2022
Symbol BOLT
Price $1.77
Beta 0.000
Volume Avg. $220.72 thousand
Market Cap $66.63 M
52 Week Range $1.39 - $17.07


Bolt Biotherapeutics, Inc. opened the day at $1.77 which is -1.72 % on yesterday's close. Bolt Biotherapeutics, Inc. has a 52 week high of $17.07 and 52 week low of $1.39, which is a difference of $15.68. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $66.63 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Bolt Biotherapeutics, Inc. for $66.63 M, it would take 15 years to get your money back. Bolt Biotherapeutics, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Bolt Biotherapeutics, Inc. Stock Forecast - Is Bolt Biotherapeutics, Inc. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreSell
ROA ScoreNeutral
DE ScoreNeutral
PE ScoreSell
PB ScoreNeutral
Overall RecommendationNeutral

Growth and Value


PE Ratio -0.681
Dividend Yiel 0.000
Net Profit Margin -27.956


Valuing Bolt Biotherapeutics, Inc.


Price Book Value Ratio 0.317 Price To Book Ratio 0.317
Price To Sales Ratio 19.045 Price Earnings Ratio -0.681


How liquid is Bolt Biotherapeutics, Inc.


Current Ratio 9.734
Quick Ratio 9.469


Debt


Debt Ratio 0.201 Debt Equity Ratio 0.251
Long Term Debt To Capitalization 0.091 Total Debt To Capitalization 0.099



Latest news about Bolt Biotherapeutics, Inc.


Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 12:20 p.m. ET (9:20 a.m. PT) in New York, New York.

Date : 31/08/2022

Bolt Biotherapeutics: A Promised Follow Up

Today, we post a promised follow-up on early stage biotech concern Bolt Biotherapeutics. The company has suffered some setbacks over the past year, but the stock now trades for approximately one-third of the cash on its balance sheet.

Date : 26/08/2022

Bolt, Orion-E to build solar plants in Brazil for about $630 million

Energy infrastructure company Orion-E has reached an agreement with energy trader Bolt to build solar photovoltaic plants in Brazil with a combined capacity of 500 megawatts (MW), a company executive said on Tuesday.

Date : 23/08/2022

Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022

- Ex vivo data support the high frequency of myeloid cells in tumors, even when T cells are not present -

Date : 27/05/2022

Hot Penny Stocks to Watch Now? 3 For Your List

Are these hot penny stocks on your list right now? The post Hot Penny Stocks to Watch Now?

Date : 12/05/2022





About Bolt Biotherapeutics, Inc.


CEO :
Sector : Healthcare
Industry : Biotechnology

Website : https://www.boltbio.com

Exchange : NASDAQ Global Select

Description :

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.


My Newsletter

Sign Up For Updates & Newsletters